EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Dual-Oriented Targeted Nanostructured SERS Label-Free Immunosensor for Detection, Quantification, and Analysis of Breast Cancer Biomarker Concentrations in Blood Serum

Mohammad E Khosroshahi iD, Christine Gaoiran, Vithurshan Umashanker iD, Hayagreev Veeru, Pranav Panday

Biosensors · 11.07.2025 · 15 (7) · 447

DOI: 10.3390/bios15070447 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Biosensors, online erschienen am 11.07.2025. Verfasst von Mohammad E Khosroshahi und 4 weiteren Autor:innen. Beteiligte Einrichtung: Nanobiophotonics & Biomedical Research Laboratory, M.I.S. Electronics Inc., Richmond Hill, ON L4B 1B4, Canada. Hauptthemen laut MEDLINE: Breast Neoplasms, Spectrum Analysis, Raman, Biomarkers, Tumor, Biosensing Techniques. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 68 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: MIS Electronics Inc., Department of R&D..

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

In clinical applications of surface-enhanced Raman spectroscopy (SERS) immunosensors, accurately determining analyte biomarker concentrations is essential. This study presents a non-invasive approach for quantifying various breast cancer biomarkers—including human epidermal growth factor receptor II (HER-II) (2+, 3+ (I), 3+ (II), 3+ (III), and positive IV) and CA 15-3—using a directional, plasmonically active, label-free SERS sensor. Each stage of sensor functionalization, conjugation, and biomarker interaction was verified by UV–Vis spectroscopy. Atomic force microscopy (AFM) characterized the morphology of gold nanourchin (GNU)-immobilized printed circuit board (PCB) substrates. An enhancement factor of ≈ 0.5 × 105 was achieved using Rhodamine 6G as the probe molecule. Calibration curves were initially established using standard HER-II solutions at concentrations ranging from 1 to 100 ng/mL and CA 15-3 at concentrations from 10 to 100 U/mL. The SERS signal intensities in the 620–720 nm region were plotted against concentration, yielding linear sensitivity with R2 values of 0.942 and 0.800 for HER-II and CA15-3, respectively. The same procedure was applied to breast cancer serum (BCS) samples, allowing unknown biomarker concentrations to be determined based on the corresponding calibration curves. SERS data were processed using the filtfilt filter from scipy.signal for smoothing and then baseline-corrected with the Improved Asymmetric Least Squares (IASLS) algorithm from the pybaselines.Whittaker library. Principal Component Analysis (PCA) effectively distinguished the sample groups and revealed spectral differences before and after biomarker interactions. Key Raman peaks were attributed to functional groups including N–H (primary and secondary amines), C–H antisymmetric stretching, C–N (amines), C=O antisymmetric stretching, NH3+ (amines), carbohydrates, glycine, alanine, amides III, C=N stretches, and NH2 in primary amides.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Breast NeoplasmsSpectrum Analysis, RamanBiomarkers, TumorBiosensing TechniquesHumansFemaleNanostructuresGoldImmunoassay

Stichwörter der Autor:innen

breast cancer biomarkersconcentration quantificationdirectional antibodygold nanourchinsurface-enhanced Raman scattering

Substanzen

Biomarkers, TumorGold

Autor:innen und Institutionen

  • Nanobiophotonics & Biomedical Research Laboratory, M.I.S. Electronics Inc., Richmond Hill, ON L4B 1B4, Canada.
  • Institute for Advanced Non-Destructive and Non-Invasive Diagnostic Technologies (IANDIT), University of Toronto, Toronto, ON M5S 3G8, Canada.
  • Department of Mechanical and Industrial Engineering, University of Toronto, Toronto, ON M5S 3G8, Canada.
  • Department of Electrical and Computer Engineering, University of Waterloo, Waterloo, ON N2L 3G1, Canada.
  • Department of Nanotechnology Engineering, University of Waterloo, Waterloo, ON N2L 3G1, Canada.

ORCID-Profile: Mohammad E Khosroshahi, Vithurshan Umashanker

Förderung

  • MIS Electronics Inc., Department of R&D.

Zitieren

APA

Khosroshahi, M. E., Gaoiran, C., Umashanker, V., Veeru, H., & Panday, P. (2025). Dual-Oriented Targeted Nanostructured SERS Label-Free Immunosensor for Detection, Quantification, and Analysis of Breast Cancer Biomarker Concentrations in Blood Serum. Biosensors, 15(7), 447. https://doi.org/10.3390/bios15070447

Vancouver

Khosroshahi ME, Gaoiran C, Umashanker V, Veeru H, Panday P. Dual-Oriented Targeted Nanostructured SERS Label-Free Immunosensor for Detection, Quantification, and Analysis of Breast Cancer Biomarker Concentrations in Blood Serum. Biosensors. 2025;15(7):447. doi:10.3390/bios15070447

BibTeX
@article{Khosroshahi2025,
  author = {Khosroshahi, Mohammad E and Gaoiran, Christine and Umashanker, Vithurshan and Veeru, Hayagreev and Panday, Pranav},
  title = {Dual-Oriented Targeted Nanostructured SERS Label-Free Immunosensor for Detection, Quantification, and Analysis of Breast Cancer Biomarker Concentrations in Blood Serum},
  journal = {Biosensors},
  year = {2025},
  volume = {15},
  number = {7},
  pages = {447},
  doi = {10.3390/bios15070447}
}
Kostenlos starten →